Abstract
BackgroundIn post hoc analyses of the BLISS trials, patients with SLE with positive anti-dsDNA and low complement (C3/C4) had a greater response to intravenous belimumab (BEL) compared with patients without...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have